Analytical Data
-
Gene name
XAGE1
- Application
-
Alternative Names
X antigen family member 1. XAGE-1. Cancer/testis antigen 12.1. CT12.1. G antigen family D member 2
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9HD64
-
Expression Region
1-69 aa
-
AA Sequence
MESPKKKNQQLKVGILHLGSRQKKIRIQLRSQVLGREMRDMEGDLQELHQSNTGDKSGFGFRRQGEDNT
-
Molecular Weight
34.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
XAGE1 is a member of the cancer/testis (CT) antigen family, which is primarily expressed in the human testis and various malignancies, including melanoma, lung cancer, and some types of breast cancer. The discovery of XAGE1 is significant due to its potential role in tumor immunotherapy, as CT antigens are often targets for cancer vaccines and other therapeutic interventions. The expression of XAGE1 in tumors but not in normal tissues, aside from the testis, makes it an attractive candidate for targeted therapies. Recent studies have focused on the generation of recombinant XAGE1 proteins to investigate their immunogenicity and potential as therapeutic agents. By expressing XAGE1 in a suitable host system, researchers aim to develop diagnostic tools and treatment modalities that harness the immune response against tumors expressing this antigen. Furthermore, recombinant XAGE1 proteins can be used to produce specific antibodies and understand the molecular mechanisms underlying its role in cancer progression, making it an essential focus of current cancer research. The exploration of XAGE1's functional properties and its interactions with immune cells could lead to novel strategies in personalized cancer treatment, providing hope for effective interventions in patients with XAGE1-expressing tumors.
